Annual Report 2019-20 Overview 001-120 Reports 121-230 Statements 231-423

Total Page:16

File Type:pdf, Size:1020Kb

Annual Report 2019-20 Overview 001-120 Reports 121-230 Statements 231-423 CIPLA LIMITED ANNUAL REPOR T 2019-20 Caring since For Life 1935 Reimagining Tomorrow Table of Contents Corporate Overview Statutory Reports Financial Statements 002 ...................................................... 014 ........................................................ 030 ...................................................... 121 ............................................................ 231 ........................................................ 424 ...................................................... Caring for life since 1935 Ten-Year Highlights Strengthening Our Communities Management Discussion and Standalone Financial Statements GRI Standard Index Analysis with Auditor’s Report 004 ..................................................... 015 ......................................................... 032 ....................................................... 434 ...................................................... About this Report Corporate Information Cipla Product Spread 142 .......................................................... 318 ........................................................ Glossary of Abbreviations Board’s Report Consolidated Financial 005 ....................................................... 016 ........................................................ 034 ....................................................... Statements with Auditor’s Report About Cipla Chairman’s Message Strategy Strengthened for a 175 ......................................................... Sustainable Tomorrow Business Responsibility Report 420 ...................................................... 006 ...................................................... 018 ........................................................ Salient Features of Financial Our First Principles Executive Vice-Chairperson’s 041 ......................................................... 182 ........................................................ Statements of Message Our Value Creation Model Report on Corporate Governance Subsidiaries and Associates 007 ...................................................... Financial Highlights 020 ...................................................... 044 ...................................................... MD & GCEO’s Message Stakeholder Engagement 008 ..................................................... Sustainability Highlights 022 ...................................................... 046 ....................................................... Creating Hope since 1935 Materiality Assessment 010 ....................................................... Global Reach 024 ...................................................... 048 ....................................................... Awards and Accolades Our Integrated Approach to Risk 012 ........................................................ Management Board of Directors 026 ...................................................... Lung Leadership 052 ...................................................... 013 ........................................................ Six Capitals as per Integrated Management Council 028 ...................................................... Reporting Framework Cipla stands strong in the battle against COVID-19 Dr Y K Hamied Samina Hamied Umang Vohra Chairman’s Executive Vice- MD & GCEO’s Message Chairperson’s Message Message “Cipla’s endeavour to ensure equitable access “We are in the business of saving lives “As the world gets a grip on the unabated to quality healthcare is entrenched in our and true to this philosophy, the people COVID-19 pandemic, I firmly believe that it also humanitarian purpose of ‘Caring for Life’ that has of your Company have demonstrated presented us with multiple opportunities to reflect Scan this code with driven our efforts in India and globally over the extraordinary dedication to help combat and reimagine the future! At Cipla, we acted with a QR reader app on past 85 years.’’ the challenges posed by COVID-19.” speed and agility; optimising overall resourcing your smartphone or tablet and know across businesses and creating a digital roadmap more about us Page No. 16 - 17 Page No. 18 - 19 for the future.” Page No. 20 - 21 Caring for life since 1935 Cipla began its Our founder Dr KA Hamied’s With its all-pervasive impact, vision - ‘Never again will India be the pandemic has changed the humble journey in starved of essential drugs’ - served dynamics of workplaces. As the 1935 with the sole as the roadmap for the enterprise new normal takes shape, our purpose of making which had at its core the lofty ideal resilience and agility powers of harnessing Indian expertise our confidence to reimagine healthcare accessible to achieve self-sufficiency in the business landscape. With to all. For over eight pharmaceuticals. technology as our biggest lever, Cipla stands ready and geared to decades the Company With its strong R&D credentials, reimagine a new tomorrow. dedicated itself manufacturing prowess and legacy of innovation, Cipla has played a For Ciplaites, a few key not just to improve critical role in managing global fundamentals – of contributing to access to quality health crises over the last 85 years. society, of making a difference, In 2001, the crusade against HIV and continually striving to make the healthcare but to saw Cipla introducing, for the world healthier and better – are make a difference in first time in the world, a unique deeply ingrained. We are hoping the lives of people fixed dose combination of triple that this makes the difference – in antiretroviral drugs at less than a tipping hope over fear. This is what and in the process USD 1 per day, saving millions of Cipla was born to do; to care for life established an lives. When the SARS pandemic and we will continue to espouse it. engulfed several parts of the world enviable international in 2003, Cipla was one of the first footprint. Today Cipla to launch a generic treatment for is ranked 3rd largest H1N1 influenza. in pharma in India Today, yet again Cipla is at the forefront of the fight against and 3rd largest in COVID-19, providing a spectrum the pharma private of treatment including remdesivir, tocilizumab and favipiravir in market in South Africa addition to other complementary and is among the most therapies. Our Government dispensed generic collaborations, strategic global partnerships and endeavours players in the U.S. with industry association further illustrates our solidarity efforts towards saving millions of lives impacted by the pandemic. Dr K A Hamied (1898 – 1972) Founder, Cipla Corporate Statutory Financial Annual Report 2019-20 Overview 001-120 Reports 121-230 Statements 231-423 About this Report1 About Cipla2 Welcoming our Our core elements Report boundary and scope Established in 1935, Cipla is a For over eight decades, making stakeholders to the to enhance value A purpose- global pharmaceutical company a difference to patients has The FY 2019-20 Integrated Report focused on responsible and inspired every aspect of Cipla’s FY 2019-20 Integrated creation covers the business activities of Cipla driven sustainable growth of complex work. Our paradigm-changing st for the financial year 1 April, 2019 to generics and deepening offer of a triple anti-retroviral Report Cipla’s FY 2019-20 Integrated 31st March, 2020. Our journey towards portfolio in our home markets therapy in HIV/AIDS at less Report adequately showcases shared value creation encompasses promise In our mission to pursue of India, South Africa and than a dollar a day in Africa in its integrated organisational Cipla’s global operations. Information sustained value creation as a North America, as well as 2001 is widely acknowledged as strategy, taking into account on our subsidiaries and joint ventures responsible pharmaceutical key regulated and emerging having contributed to bringing important risks and valued has been showcased wherever Company, we are proud to With over eight markets. Our strengths in the inclusiveness, accessibility inputs from the Stakeholder appropriate, to enhance our disclosures present our third Integrated respiratory, anti-retroviral, and affordability to the centre Engagement and Materiality and provide a holistic view of our decades of Caring Annual Report. This Report aims urology, cardiology, anti- of the HIV movement. A Assessment (SEMA). Our report operational excellence. Exclusions are for Life, we have to provide detailed insights into provided in the respective sections. infective and CNS as well responsible corporate citizen, is defined by the contours of our financial and non-financial adopted a patient- as other key therapeutic Cipla’s humanitarian approach the material topics derived and performance encompassing segments are well-known. Our to healthcare in pursuit of its further elaborated in our six centric approach in our leadership, culture and Responsibility Statement 46 manufacturing sites around purpose of Caring for Life and <IR> Capitals. We also endeavor strategy and to showcase our safeguarding their the world produce 50+ dosage deep-rooted community links to ensure that this Report The Board believes that Cipla’s value creation process to our forms and 1,500+ products wherever it is present, make it addresses the impact and use of FY 2019-20 Integrated Report addresses interests through stakeholders. using cutting-edge technology a partner of choice for global the Capitals on our strategy and all material topics, offers a balanced high quality platforms to cater to our 80+ health bodies and
Recommended publications
  • MARKET LENS 15147 Intraday Pick MARUTI Resistance 15349 Intraday Pick SUNTV 15397 Intraday Pick BALKRISIND
    Institutional Equity Research NIFTY 15301 IN FOCUS May 27 2021 Support 15224 Stock in Focus BAJAJ FINANCE MARKET LENS 15147 Intraday Pick MARUTI Resistance 15349 Intraday Pick SUNTV 15397 Intraday Pick BALKRISIND EQUITY INDICES Indices Absolute Change Percentage Change Domestic Last Trade Change 1-D 1-Mth YTD BSE Sensex 51,018 380.0 0.8% 2.6% 6.8% CNX Nifty 15,301 93.0 0.6% 2.9% 9.4% S&P CNX 500 13,022 59.2 0.5% 4.0% 13.1% SENSEX 50 16,024 99.0 0.6% 3.0% 9.5% International Last Trade Change 1-D 1-Mth YTD DJIA 34,323 10.6 0.0% 1.5% 12.1% NASDAQ 13,738 80.8 0.6% (2.2%) 6.6% NIKKEI 28,469 (173.2) (0.6%) (2.0%) 3.7% HANGSENG 29,177 20.9 0.1% 0.4% 7.2% ADRs / GDRs Last Trade Change 1-D 1-Mth YTD Dr. Reddy’s Lab (ADR) 72.0 (0.8) (1.1%) 5.8% 1.0% STOCK IN FOCUS Tata Motors (ADR) 21.8 0.4 1.8% 6.5% 72.7% f BAF is focused on the mass-affluent segment. Additionally, it Infosys (ADR) 19.3 0.5 2.8% 5.7% 13.6% ICICI Bank (ADR) 18.0 0.3 1.7% 7.2% 20.9% enjoys significant pricing power in its shorter-tenor and small-ticket HDFC Bank (ADR) 74.0 1.0 1.3% (0.4%) 2.4% unsecured loans, as the change in EMI (for each percentage point Axis Bank (GDR) 50.6 0.4 0.8% 7.6% 19.6% increase in interest rate) is lower for the short-tenor small-ticket loans.
    [Show full text]
  • Motherson Sumi Systems (MSS IN)
    Motherson Sumi Systems (MSS IN) Rating: BUY | CMP: Rs62 | TP: Rs115 March 18, 2020 Shutdown in Europe while China resumed – Upgrade to BUY Company Update Quick Pointers: ☑ Change in Estimates | ☑ Target | ☑ Reco . MSS hosted a call where it indicated production shutdown in Europe for 15 Change in Estimates days while China has resumed considerably. Current Previous FY21E FY22E FY21E FY22E Rating BUY ACCUMULATE . With ~37% of SMRP BV revenues contribution consisting from European Target Price 115 153 Sales (Rs. m) 722,331 811,681 750,749 845,246 markets, where we see transitionary issues to persist at-least over 1QFY21. % Chng. (3.8) (4.0) EBITDA (Rs. m) 59,306 74,158 69,071 80,291 We cut FY20/21/22 EPS estimates by 8%/18%/11% to factor in for production % Chng. (14.1) (7.6) EPS (Rs.) 5.5 7.2 6.7 8.1 shut down in China and Europe due to COVID-19. ~37% of SMRP BV revenues % Chng. (18.7) (11.0) consisting from European markets, where we see transitionary issues to persist at-least over 1QFY21. However, on the positive side, operations in Key Financials - Consolidated China have recovered substantially with ~26 plants is now operational out of Y/e Mar FY19 FY20E FY21E FY22E total 27. Whereas other key markets like US, South America and UK hasn’t Sales (Rs. bn) 635 662 722 812 EBITDA (Rs. bn) 53 52 59 74 seen any shutdowns so-far. We believe, significant correction presents an Margin (%) 8.4 7.8 8.2 9.1 opportunity to buy this stock at an attractive valuation at 11x FY21 estimates.
    [Show full text]
  • Investor Presentation May 2016
    Investor Presentation May 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. 2 Agenda Biocon: Who are we? Highlights • Business Highlights • Financial Highlights Growth Segments •
    [Show full text]
  • CIPLA, Ltd. CIPLA Ltd Is a Pharmaceutical Company Based in India
    CIPLA Ltd. And the Provision of Anti-AIDS Pharmaceuticals It’s 2001, and G. G. Brereton is a busy man. He heads the Global Intellectual Property Office at GlaxoSmithKline (GSK), a multinational pharmaceutical corporation with operations throughout the world. He is tasked with defending GSK’s patents against foreign imitators. In recent months he has been occupied with infringements against GSK patents for antiretroviral drugs – the pharmaceuticals used to treat the symptoms of HIV and AIDS. This week has been especially hectic: CIPLA Ltd. of India has just announced its offer to supply an antiretroviral “cocktail” to Sub-Saharan African countries for 3 percent of the price that GSK charges for its anti-AIDS cocktail. Top management at GSK wants options for responding to this surprising offer. G. G. has been given the job of (1) coming up with potential responses by GSK to this initiative and (2) identifying that option that best assures the continued profitability of the firm now and into the foreseeable future. He has till Friday to do it! HIV/AIDS. One of the most vexing public-health problems of the new century has been the explosion in cases of human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS). In the year 2000, the United Nation AIDS Organization (UNAIDS) reported that 36.1 million people worldwide were living with HIV or AIDS. There were 5.3 million new cases of HIV infection in the year, and 3.0 million deaths attributable to HIV infection. Since its first diagnosis, the AIDS epidemic has claimed 21.8 million lives.
    [Show full text]
  • Cipla Ltd (CIPLA)
    Cipla Ltd (CIPLA) CMP: | 826 Target: | 975 (18%) Target Period: 12 months BUY January 30, 2021 Strong growth in India, RoW; better margins… Q3 revenues grew 18.2% YoY to | 5169 crore led by strong growth in domestic and RoW markets. Domestic sales grew 25.5% YoY to | 2231 crore. RoW markets business grew 47.2% YoY to | 823 whereas South Particulars Africa business fell 2.5% YoY to | 579 crore. US grew 9.6% YoY to | 1037 crore. EBITDA margins expanded 647 bps YoY to 23.8% mainly due to P articular Am ount significantly lower other expenditure. Hence, EBITDA grew 62.3% YoY to | Market Capitalisation | 66581 crore 1231 crore. PAT more than doubled to | 748 crore vs. | 351 crore in Q3FY20. Debt (FY20) | 2816 crore Cash (FY20) | 1004 crore Result Update Result Product launches, front-end shift key for formulation exports E V | 68393 crore 52 week H/L (|) 870/357 Formulation exports comprise ~54% of FY20 revenues. The company is E quity capital | 161.3 crore focusing on front-end model, especially for the US, along with a gradual shift from loss making HIV and other tenders to more lucrative respiratory and F ace value | 2 Price performance other opportunities in the US and EU. We expect export formulation sales to grow at 9.8% CAGR to | 12242 crore in FY20-23E. Key drivers will be a launch of inhalers (drug-device) and other products in developed markets. 1000 14000 12000 800 Indian formulations growth backed by new launches 10000 600 8000 With ~5% market share, Cipla is the third largest player in the domestic 400 6000 formulations market.
    [Show full text]
  • Domestic Institutional Philanthropy in India
    Charting a course post COVID-19 Supported by Delivering High Impact SEP 2020 Published by Sattva in September 2020. Supported by the Bill & Melinda Gates Foundation. Email [email protected] Website www.sattva.co.in Lead Researchers Aarti Mohan, Sanjana Govil, Bhavin P Chhaya Research, Analysis Prachur Goel, Shalini Rajan, and Production Mansi Agarwal, Palagati Lekhya Reddy, Ashwini Rajkumar, Radhika Bose, Gayatri Malhotra, Brooke VanSant, Anushka Bhansali Project Advisors Karuna Segal, Arnav Kapur, Anjani Kumar Singh (Bill & Melinda Gates Foundation), Srikrishna Sridhar Murthy (Sattva Consulting) Design and Bhakthi Dakshinamurthy Typesetting [email protected] Cover Photo Axis Bank Foundation We are grateful to 74 leaders representing 47 organisations in the domestic institutional philanthropy ecosystem who generously shared their expertise and insights for this report (See Annexure 3 for a complete List of Interviews). This work is licensed under the Attribution-Non Commercial-ShareALike 4.0 International License: Attribution - You may give appropriate credit, provide a link to the license, and indicate if any changes were made. NonCommercial - You may not use the material for commercial purposes. ShareALike - If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. About this study 01 Introduction 04 Executive summary 06 The landscape before and after COVID-19 08 Trends in intervention strategies 15 Trends in programme implementation 20 Programme trends per sector 27 Agricultural livelihoods Water and sanitation Women’s empowerment and digital financial inclusion Health systems and delivery Approaches to scale and collaboration 36 Annexures 41 Explanation of terms Study scope and methodology List of interviews Endnotes About 51 Dr.
    [Show full text]
  • Dashboard the Monthly Auto Update
    June 2014 Dashboard The Monthly Auto Update Data Track: June 2014 volume update of auto majors Speedometer Sector overview and outlook ........................................................... 2 June 2014 relative performance Hero MotoCorp ................................................................................. 3 Bajaj Auto .......................................................................................... 4 HMSI .................................................................................................. 6 TVS Motor .......................................................................................... 7 Maruti Suzuki .................................................................................... 9 Mahindra & Mahindra ..................................................................... 11 Tata Motors ...................................................................................... 13 Ashok Leyland ................................................................................. 15 Eicher Motors .................................................................................. 16 Sector Gauge: May 2014 update 12-month relative performance Two-wheelers ................................................................................. 17 Three-wheelers .............................................................................. 19 Cars and UVs .................................................................................... 21 Commercial vehicles......................................................................
    [Show full text]
  • Model Portfolio Update
    Model Portfolio update January 21, 2016 LatestDeal Team Model – PortfolioAt Your Service Large cap Midcap Name of the company Weightage(%) Name of the company Weightage(%) Auto 14 Aviation 6 Tata Motor DVR 4 Interglobe Aviation 6 Bosch 3 Auto 6 Maruti 4 Bharat Forge 6 EICHER Motors 3 BFSI 6 BFSI 23 BjjFiBajaj Finserve 6 HDFC Bank 8 Capital Goods 6 Axis Bank 3 HDFC 8 Bharat Electronics 6 Bajaj Finance 4 Cement 6 Capital Goods 5 Ramco Cement 6 L & T 5 Consumer 24 Cement 3 Symphony 6 UltraTech Cement 3 Supreme Ind 6 FMCG/Consumer 14 Kansai Nerolac 6 ITC 7 Pidilite 6 United Spirits 2 FMCG 8 Asian Paints 5 Nestle 8 IT 21 Infrastructure 8 Infosys 10 NBCC 8 TCS 8 Oil & Gas 6 Wipro 3 Meida 2 CtlCastrol 6 Zee Entertainment 2 Logistics 6 Metal 2 Container Corporation of India 6 Tata Steel 2 Pharma 12 Oil & Gas 4 Natco Pharma 6 Reliance Industries 4 Torrent Pharma 6 Pharma 12 Textile 6 Lupin 5 Arvind 6 Dr Reddys 4 Total 100 Aurobindo Pharma 3 Total 100 • Exclusion - Eicher Motors, Bajaj Finance (transferred to large cap), PVR, • Exclusion- State Bank of India, Bharti Airtel and ONGC CARE, Cummins & Shree Cement • Inclusion – Eicher Motors, Bajaj Finance (transferred from midcap), Wipro, • Inclusion – Ramco Cement, Bajaj Finserv, Supreme Industries, Indigo, Reliance Industries & Aurobindo Pharma Pidilite, Bharat Electronics and Bharat Forge Source: Bloomberg, ICICIdirect.com Research *Diversified portfolio - Combination of 70% large cap and 30% midcap portfolio OutperformanceDeal Team – At continues Your Service across all portfolios… • Our indicative large cap equity model portfolio (“Quality -20”) has • In the large cap space we continue to remain positive on pharma & IT.
    [Show full text]
  • Flag Bearer of the Recovery in Automotive Segment
    Sector Report 2 Wheelers 28th August, 2020 Auto 2 Wheelers in a sweet spot – Flag bearer of the recovery in Automotive Segment Indian two-wheelers faced a severe downturn in FY20 and are expected to fall further in FY21 due to COVID-19 and BSVI cost push; however, volumes should rebound by FY22E and FY23E on two years of low base. In light of COVID-19 pandemic, we expect the industry volumes to fall by ~12% in FY21E, followed by strong growth of ~18% and ~14% in FY22E and FY23E. We are bullish on the Indian 2W industry over the next 2-3 years. The auto volumes are back by almost adecade whereas the margins are at cyclical lows; we expect multi-fold earnings growth in the recovery period. We believe Hero Motocorp Ltd will outperform its peers on the back of strong rural demand and preference for entry-level motorcycles. Eicher Motors with its strong franchise and a renewed focus on new products is expected to do well. We are of the opinion that TVS Motors is trading at significantly higher multiples in comparison to other 2 wheeler OEMs and hence we expect limited upside from current levels. We assume coverage on the two-wheeler industry with a BUY rating on Hero Motocorp Ltd (Hero), HOLD rating on Eicher Motors Ltd (EIM) and a SELL rating on TVS Motors Ltd (TVSL). We upgrade our rating from HOLD to BUY on Bajaj Auto Ltd (BJAUT). Covid-19 and Key Regulatory Changes amidst weak cycle India's two-wheeler (2W) industry saw its worst downturn in a decade as volumes fell by 18% YoY in FY20 amid weakening economy and regulatory changes leading to higher insurance and road tax.
    [Show full text]
  • Cipla Limited
    Cipla Limited Registered Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013 Phone: (9122) 2482 6000, Fax: (9122) 2482 6893, Email: [email protected], Website: www.cipla.com Corporate Identity Number: L24239MH1935PLC002380 Annexure to the Board’s Report Particulars of employee remuneration for the financial year ended 31st March, 2019 As required under section 197(12) of the Companies Act, 2013, read with rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Employed throughout the year Name Designation Qualification Experience Age Date of Last employment Remuneration (in years) (in years) Employment (Rs.) Abhay Kumar Chief Talent Officer Master of Arts / 17 53 3/10/2016 Piramal Pharma 15,034,298.00 Srivastava Master of Personal Solutions Management Ademola Olukayode Head - Quality Doctorate / MPH / B. 17 48 20/6/2018 US FOOD AND DRUG 17,982,961.00 Daramola Compliance & Tech. ADMINISTRATION Sustainability (US FDA) Ajay Luharuka Head Finance - IPD, B.com,MMS,CFA 23 46 11/7/1996 NIIT Limited 11,922,994.00 API, Specialty & Global Respi Aliakbar Rangwala Senior Business Head M. Sc. / B. Sc. 19 42 19/1/2009 NA 10,677,779.00 - Chronic & Emerging - India Business Alpana Vartak Head - Talent MBA (HR) / B. Sc. 15 41 8/1/2018 Coco - Cola 10,312,782.00 Acquisition Company Anil Kartha Site Head - Bsc, Bpharm 28 56 27/5/1991 Vysali 12,525,338.00 Patalganga - Pharmaceuticals Formulations Anindya Kumar Shee Head - Organization B. Tech. / MBA 18 48 14/1/2016 Reliance Industries 11,084,298.00 Development Ltd.
    [Show full text]
  • “Sequential Recovery Witnessed in Passenger Vehicles & 2-Wheeler Segment” Auto Sector: Focus Stocks
    “Sequential Recovery Witnessed in Passenger vehicles & 2-Wheeler segment” Auto Sector: Focus Stocks Maruti Suzuki/Tata Motors/ Bajaj Auto/Eicher Motors Q1FY21 Post Earnings Review 18th August 2020 Table of Contents 1 Q1FY21 Earnings Summary – Key Takeaways 4 2 Earnings Review: Result Summary 5 - 8 3 Valuation Snapshot 9 - 12 4 Performance Overview 13 - 17 KRChoksey Research ANALYST Phone: +91-22-6696 5555, Fax: +91-22-6691 9576 is also available on Bloomberg KRCS<GO> www.krchoksey.com Parvati Rai, [email protected], +91-22-6696 5413 Thomson Reuters, Factset and Capital IQ Coverage Companies Passenger Vehicles • Maruti Suzuki Ltd • Tata Motors Ltd 2/3-Wheelers • Bajaj Auto Ltd • Eicher Motors Ltd KRChoksey Research ANALYST Phone: +91-22-6696 5555, Fax: +91-22-6691 9576 is also available on Bloomberg KRCS<GO> www.krchoksey.com Parvati Rai, [email protected], +91-22-6696 5413 Thomson Reuters, Factset and Capital IQ Q1FY21 Earnings Outlook – Key Takeaways Passenger & 2-Wheelers segment show recovery; Upcoming festive season & Rural market to drive demand Green-Shoots in Passenger vehicles and Two-Wheelers, while Commercial Vehicle remains challenging • As per SIAM, In July-20, Industry Passenger Vehicle (PV) sales declined by 3.9% YoY at 182,779 units while 2-Wheelers (2-W) registered a decline of 15.2% YoY which was significantly better than preceding months wherein in Q1FY21, PV sales were down 63% YoY while that of 2-W were down by 60.5% YoY • CV segment performance will remain challenging due to high axle norms, delayed
    [Show full text]
  • Business Organizations
    CHAPTER 3 BUSINESS ORGANIZATIONS LEARNING OUTCOMES After studying this unit, you will be able to: w Have an overview of corporate history of some of the selected Indian and Global companies. w Gain information about management teams of selected companies. w Know the vision, mission and core values of dierent companies. w Know the market and nancial performance of dierent companies. w Gain vital information on products and services of famous brands of dierent companies. w Analyse a company’s information as a business analyst. © The Institute of Chartered Accountants of India ICAI _ICAI_Business and Commercial Konwledge_Chp_03-nw.indd 1 7/27/2017 3:53:35 PM 3.2 BUSINESS AND COMMERCIAL KNOWLEDGE CHAPTER OVERVIEW OVERVIEW OF SELECTED COMPANIES INDIAN COMPANIES GLOBAL COMPANIES • Adani Ports and Special Economic Zone Ltd. • Deutsche Bank • Asian Paints Ltd. • American Express • Axis Bank Ltd. • Nestle • Bajaj Auto Ltd. • Microsoft Corporation • Bharti Airtel Ltd. • IBM Corporation • Bharat Petroleum Corporation Ltd. • Intel Corporation • Cipla Ltd. • HP • Coal India Ltd. • Apple • Dr. Reddy’s Laboratories Ltd. • Walmart • GAIL (India) Ltd. • HDFC Bank Ltd. • ICICI Bank Ltd. • Indian Oil Corporation Ltd. • Infosys Ltd. • ITC Ltd. • Larsen & Toubro Ltd. • NTPC Ltd. • Oil & Natural Gas Corporation Ltd. • Power Grid Corporation of India Ltd. • Reliance Industries Ltd. • State Bank of India • Tata Sons Limited • Wipro Ltd. © The Institute of Chartered Accountants of India ICAI _ICAI_Business and Commercial Konwledge_Chp_03-nw.indd 2 7/27/2017 3:53:35 PM BUSINESS ORGANIZATIONS 3.3 3.1 INTRODUCTION A company overview is the most eective way to acquire business intelligence and gain vital information about a company, its businesses, their products, services and processes, prospects, customers, suppliers, competitors; etc.
    [Show full text]